Navigating Ethics in Global Longevity Research: An Analysis of XPRIZE Healthspan’s Clinical Trial Framework

Many societies around the world face a decline in per capita fertility rates and aging populations, threatening the sustainability of pensions, healthcare systems, and overall economic productivity. In response, the field of geroscience seeks to develop interventions targeting the biology of aging to delay age-related diseases and extend healthspan, promising to help individuals live healthier and longer lives. This article examines the ethical dimensions of XPRIZE Healthspan, a global initiative launched in 2023 to advance longevity biotechnology and extend the period of life spent in good health. With a $101 million prize purse, this competition engages over 600 teams globally to develop interventions for functional restoration and the prevention of chronic diseases associated with aging. The analysis leverages Emanuel, Wendler, and Grady’s 2000 ethical framework for clinical research, analyzing principles such as scientific validity, informed consent, and equitable participant selection. While XPRIZE Healthspan emphasizes methodological flexibility and participant autonomy, the article identifies potential challenges in ensuring ethical oversight, participant safety, and equitable access to resulting innovations. This article critically evaluates the trade-offs between decentralized governance and the necessity for robust ethical practices, emphasizing the importance of independent review, transparent data handling, and long-term societal implications. Beyond clinical trials, the initiative serves as a platform to redefine societal perceptions of aging and foster dialogue on the ethical, regulatory, and societal dimensions of geroscience. By addressing these ethical challenges, XPRIZE Healthspan has the potential to establish a transformative paradigm in health and aging research while fostering global collaboration and public trust. This work is based on the analysis of XPRIZE documentation and participation in multiple longevity biotechnology conferences over the past two years.